ArticleMicroorganisms2021
Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG.
Open access · goldAbstract read
In one paragraph
Article in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- An Indirect Comparison of Diagnostic Accuracy for Seven Different SARS-CoV-2 Serological Assays: A Meta-Analysis and Adjusted Indirect Comparison of Diagnostic Test Accuracy.Influenza and other respiratory viruses · 2025Pooled it
- Dynamics of SARS-CoV-2 seroassay sensitivity: a systematic review and modelling study.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023Pooled it
- Unleashing Monoclonal Antibodies: Targeting Covid-19's Nucleocapsid Protein and Spike Antigens.Archives of Razi Institute · 2025Article
- Humoral immune response and live-virus neutralization of the SARS-CoV-2 omicron (BA.1) variant after COVID-19 mRNA vaccination in children and young adults with chronic kidney disease.Pediatric nephrology (Berlin, Germany) · 2023Article
- Development of a cost-effective quantitative in-house ELISA assay for screening anti-S1 IgG antibodies targeting SARS-CoV-2.Journal of medicine and life · 2023Article
- Article
- Numerical optimization of microfluidic biosensor detection time for the SARS-CoV-2 using the Taguchi method.Indian journal of physics and proceedings of the Indian Association for the Cultivation of Science (2004) · 2023Article
- Article
- Article
- Evaluation of S- and M-Proteins Expressed inPathogens (Basel, Switzerland) · 2022Article
- Immune Response to Third and Fourth COVID-19 Vaccination in Hemodialysis Patients and Kidney Transplant Recipients.Viruses · 2022Article
- Nanomaterial and interface advances in immunoassay biosensors.The journal of physical chemistry. C, Nanomaterials and interfaces · 2022Article
- A Quantitative ELISA to Detect Anti-SARS-CoV-2 Spike IgG Antibodies in Infected Patients and Vaccinated Individuals.Microorganisms · 2022Article
- Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccination.Future oncology (London, England) · 2022Article
- Seroprevalence and infection attack rate of COVID-19 in Indian cities.Infectious Disease Modelling · 2022Article
- Sensitive and specific serological ELISA for the detection of SARS-CoV-2 infections.Virology journal · 2022Article
- Diagnostic Performance of Three ELISAs for Detection of Antibodies against SARS-CoV-2 in Human Samples.TheScientificWorldJournal · 2022Article
- Surrogate test performance for SARS-CoV-2 neutralizing antibodies (nAbs) for convalescent plasma (CCP): How useful could they be?Transfusion · 2021Article
- Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers.The Journal of infection · 2021Article
- Prevalence of Anti-SARS-CoV-2 Antibodies in Poznań, Poland, after the First Wave of the COVID-19 Pandemic.Vaccines · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 1 country.
Kirsten Alexandra EberhardtDepartment of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine & I. Department of Medicine, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.ORCID 0000-0002-1002-0326
Felix DewaldInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50935 Cologne, Germany.
Eva HegerInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50935 Cologne, Germany.
Lutz GieselmannInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50935 Cologne, Germany.
Kanika VanshyllaInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50935 Cologne, Germany.ORCID 0000-0003-4552-9170
Maike WirtzInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50935 Cologne, Germany.
Franziska KleipassInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50935 Cologne, Germany.
Wibke JohannisInstitute for Clinical Chemistry, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany.
Philipp SchommersInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50935 Cologne, Germany.
Henning GruellInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50935 Cologne, Germany.ORCID 0000-0002-0725-7138
Karl August BrensingNierenzentrum Bonn, Godesberger Allee 26, 53175 Bonn, Germany.
Roman-Ulrich MüllerCenter for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany.ORCID 0000-0001-6910-0745
Max AugustinDepartment I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany.ORCID 0000-0002-2300-9337
Clara LehmannCenter for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany.
Manuel KochCenter for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany.ORCID 0000-0002-2962-7814
Florian KleinInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50935 Cologne, Germany.ORCID 0000-0003-1376-1792
Veronica Di CristanzianoInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50935 Cologne, Germany.ORCID 0000-0003-1604-8386
University of Cologne · DENierenzentrum Heidelberg · DEUniversität Hamburg · DE
Funding
Bundesministerium für Bildung und Forschung COVIM: "NaFoUniMedCovid19" (FKZ: 01KX2021)Deutsche Forschungsgemeinschaft CRC 1279; CRC 1310; FOR2722European Research Council ERC-StG639961
Abstract
PubMed holds no abstract for this paper.
Indexed as
antibodycoronavirusCOVID-19humoral responseneutralizationnon-responderpandemicprotectionsensitivitytiter
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.